The global chlamydia diagnostics market, valued at US$ 1.17 billion in 2022, is expected to witness substantial growth, reaching US$ 1.30 billion in 2023 and projected to soar to US$ 3.69 billion by 2033, with a compound annual growth rate (CAGR) of 11%. This robust expansion is fueled by several key factors including growing public awareness, technological advancements, and the increasing need for early disease detection.
Chlamydia trachomatis, a sexually transmitted bacterial infection, remains one of the most prevalent sexually transmitted infections (STIs) globally. If left untreated, it can lead to severe health complications such as pelvic inflammatory disease, infertility, and ectopic pregnancy. Thus, the demand for effective diagnostic tests and devices to detect and diagnose chlamydia is on the rise.
Get Your Report Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-16838
From 2018 to 2022, the chlamydia diagnostics market experienced a steady growth trajectory, boasting a CAGR of 8%. However, with the advent of advanced technologies and heightened awareness among the populace regarding the importance of early disease detection, the market is poised for even greater expansion in the coming years.
“The escalating prevalence of chlamydia infections worldwide underscores the urgent need for reliable diagnostic solutions,” commented FMI. “Our commitment to developing innovative diagnostic tests and devices aims to address this pressing global health concern and improve patient outcomes.”
The global chlamydia diagnostics market encompasses a wide array of diagnostic tests and devices specifically designed for the detection and diagnosis of Chlamydia trachomatis. As the market continues to evolve, stakeholders are increasingly focusing on research and development initiatives to introduce novel solutions that enhance accuracy, efficiency, and accessibility of chlamydia diagnostics.
With the projected surge in market size, industry players are poised to capitalize on emerging opportunities and drive innovation in the chlamydia diagnostics landscape. As governments and healthcare organizations prioritize efforts to curb the spread of STIs and promote sexual health awareness, the chlamydia diagnostics market is expected to play a pivotal role in advancing public health initiatives worldwide.
Key Takeaways from the Market Study:
- By test type, NAATs are expected to hold 49% of the market share in 2023 for Chlamydia diagnostics market.
- The global Chlamydia diagnostics market is expected to grow with a 11% CAGR during 2023 to 2033.
- North America is expected to possess 48% market share for Chlamydia diagnostics market in 2023.
- Europe Chlamydia diagnostics market size is expected to possess 46% market share in 2023.
“Many organizations and governments are taking steps to raise awareness about the risks of STIs and the importance of early diagnosis and treatment. This, in turn, is expected to drive the growth of the market.” states an FMI analyst
Request Methodology Now: https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16838
Competitive Landscape:
Key players in the chlamydia diagnostics market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Hologic, Inc., Quidel Corporation, DiaSorin SpA Becton, Dickinson and Company, Bio-Rad Laboratories, Pfizer, Inc., AstraZeneca and Teva Pharmaceuticals
- Abbott has Laboratories collaborated with BASHH to develop and distribute the BASHH Chlamydia Quality Assurance Scheme. This program aims to improve the quality of chlamydia testing in clinical laboratories by providing a framework for quality assurance and standardization.
- The Roche has developed Cobas 4800 CT/NG test is a nucleic acid amplification test (NAAT) that can detect the DNA of both Chlamydia trachomatis and Neisseria gonorrhoeae in various clinical samples, such as urine, swabs, and endocervical samples. The assay is highly sensitive and specific and has been widely adopted by clinical laboratories for chlamydia and gonorrhea testing.
Key Segments Profiled in the Chlamydia Diagnostics Industry Survey:
Test Type:
- Culture Tests
- Nucleic Acid Amplification Tests (NAAT)
- Direct Fluorescent Antibody Tests
- Serology Tests
End User:
- Hospitals
- Clinics
- Diagnostic Centres
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Purchase Now to Access: https://www.futuremarketinsights.com/checkout/16838
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube